Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

log into MY ENETS

ENETS Abstract Search

#992 Phase 1 and Phase 2 Clinical Trials Investigating Targets Against the Molecular Hallmarks of Gastroenteropancreatic Neuroendocrine Tumors

Introduction: Recently there have been many advances in the diagnosis and treatment of gastroenteropancreatic neuroendocrine tumors (GEP NETs), accompanied by significant improvements in our understanding of GEP NET biology. A number of well-established or novel molecular hallmarks are involved in GEP NET tumorigenesis and may help in identifying potential diagnostic or therapeutic targets.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Tamagno G

Authors: Tamagno G, Crespo G, Fierro Maya F, Fossmark R, Igaz P,

Keywords: neuroendocrine tumor, clinical trial, hallmark,

#612 Serotonin in Blood: Assessment of its Origin by Concomitant Determination of β-Thromboglobulin (platelets) and Chromogranin A (enterochromaffin cells)

Introduction: Serotonin is produced in enterochromaffin (EC) cells, taken up and stored in platelets and released during platelet activation. Measurement of platelet-poor plasma serotonin is difficult, mainly due to platelet activation during blood sampling.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Hauso �

Authors: Zeinali F, Fossmark R, Hauso �, Wiseth R, Hjertner �,

Keywords: β-thromboglobulin, serotonin, neuroendocrine tumor,

#406 YF476, a Gastrin Receptor Antagonist, Causes Regression of Tumors and Normalizes Serum Chromogranin A in Patients with Type 1 Gastric Carcinoids

Introduction: Chronic atrophic gastritis (CAG) results in achlorhydria, hypergastrinemia and, in some patients, gastric carcinoids (type 1 GCs). Type 1 GCs may become malignant and metastasize. Current treatments of type 1 GCs, such as polypectomy, somatostatin analogues and antrectomy, have their disadvantages. YF476 – a potent, selective, orally active and well-tolerated gastrin receptor antagonist in pre-clinical studies – prevented, as well as reduced, the number and size of gastric carcinoids and carcinomas in rodent models.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Fossmark R, Sørdal �, Jianu C, Qvigstad G, Boyce M,

Keywords: gastric carcinoids, gastrin, chromogranin A,